Belgium: Karo Pharma acquires Sylphar Int for €290m and intends rights issue of €200m-€250m

Sweden-based Karo Pharma, which owns and commercialises branded, original over-the-counter products and prescription medicines, has acquired Belgium-based Sylphar International for €290m (US$327m) on a cash and debt-free basis. There is the potential for an additional payment of €10m should certain conditions in relation to future growth targets be met. The transaction, expected to complete in…

You must be a HMI Subscriber to view this content.

Subscribe Now »